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Introduction: Parkinson's disease dementia (PDD) is associated with poorer quality of life (QoL). Prior to
the onset of PDD, many patients experience progressive cognitive impairment. There is a paucity of
longitudinal studies investigating the effects of cognitive decline on QoL. This study aimed to determine
the longitudinal impact of cognitive change on QoL in an incident PD cohort.
Methods: Recently diagnosed patients with PD (n ¼ 212) completed a schedule of neuropsychological
assessments and QoL measures; these were repeated after 18 (n ¼ 190) and 36 months (n ¼ 158). Mild
cognitive impairment (PD-MCI) was classified with reference to the Movement Disorder Society criteria.
Principal component analysis was used to reduce 10 neuropsychological tests to three cognitive factors:
attention, memory/executive function, and global cognition.
Results: Baseline PD-MCI was a significant contributor to QoL (b ¼ 0.2, p < 0.01). For those subjects (9%)
who developed dementia, cognitive function had a much greater impact on QoL (b ¼ 10.3, p < 0.05).
Multivariate modelling showed attentional deficits had the strongest predictive power (b ¼ 2.3,
p < 0.01); brief global tests only modestly predicted decline in QoL (b ¼ 0.4, p < 0.01).
Conclusions: PD-MCI was associated with poorer QoL over three years follow up. Cognitive impairment
had a greater impact on QoL in individuals who developed dementia over follow-up. Impaired attention
was a significant determinant of QoL in PD. Interventions which improve concentration and attention in
those with PD could potentially improve QoL.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Cognitive impairment is a common non-motor symptom in
Parkinson's disease (PD), with up to 80% of patients eventually
developing dementia (PDD) [1]. PDD is distressing for patients and
their carers and has been significantly associated with poor quality
of life (QoL) in people with PDD and carer burden [2]. As PD pro-
gresses, motor and non-motor symptoms, can negatively impact on
QoL and wellbeing [3,4], but a large prospective study found the
development of non-motor symptoms over two years had the, Faculty of Medical Sciences,
, UK.
urn).
r Ltd. This is an open access articlegreatest impact on QoL [4].
It is vital to understand which factors may impact on QoL in
those with PD. It has been suggested that cognitive impairment
may impair activities of daily living (ADL) [5], resulting in poorer
QoL. Cognitive impairment has been shown to reduce task-oriented
coping in PD patients which contributed to poorer QoL [6]. How-
ever, there is a paucity of studies investigating the long term
changes of QoL in PD, and in particular, the association with
changes in cognitive function.
This study investigated the longitudinal relationship between
cognitive function and QoL from PD diagnosis to 36 month follow
up. A secondary aim was to determine whether there was an
optimal measure of cognition in our schedule of neuropsychologi-
cal assessments which would predict QoL. We hypothesised thatunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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months would have a significantly poorer QoL compared with
subjects who maintained a stable or normal cognition during the
follow-up period.2. Methods
2.1. Participants
Between June 2009 and December 2011, newly diagnosed PD
patients from community and outpatient clinics in Newcastle-
upon-Tyne, Gateshead and Cambridgeshire, UK were invited to
participate in the Incidence of Cognitive Impairments in Cohorts
with Longitudinal Evaluation in Parkinson's disease (ICICLE-PD)
study [7]. Participants were subsequently re-assessed at 18 month
intervals. Idiopathic PD was diagnosed by a movement disorder
specialist and fulfilled Queen's Square Brain Bank criteria [8]. Of
682 people invited to take part in the ICICLE-PD study, 226 con-
sented, 312 declined to take part and the remaining individuals
were excluded (Fig. 1). Participants were excluded if they hadFig. 1. Flow diagram of subject participation. ICICLE-PD study ¼ Incidence of cognitive
impairments in cohorts with longitudinal evaluation in Parkinson's disease.significant cognitive impairment at presentation (Mini Mental State
Examination (MMSE) < 24) or a pre-existing diagnosis of dementia
[9]. Healthy control subjects (n ¼ 99) were recruited from the
community to provide age, sex and culturally appropriate norma-
tive data. Power calculations determined 98% power (effect
size ¼ 0.05) for PD vs. control groups (a ¼ 0.05, two tailed).
This study was approved by the Newcastle and North Tyneside
Research Ethics Committee. All subjects provided written informed
consent at each time point. Capacity was assessed in accordance
with the Mental Capacity Act 2005, England; participants were
deemed to have capacity to consent if they were able to satisfy the
researcher that they understood they were attending for a research
study and relate back to the researcher the tests and assessments
they would be asked to do. All participants in this study had the
capacity to give informed consent.
2.2. Assessments
Demographic information, including age, sex, and education
was collected. Participants completed the Movement Disorder So-
ciety (MDS) Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Part III [10], the National Adult Reading Test (NART) [11] as a
measure of pre-morbid IQ, and the Geriatric Depression Scale (GDS-
15) [12]. Participants were assessed in an “on” motor state. Levo-
dopa equivalent dose (LED) was calculated using methods
described by Tomlinson et al. [13]. The summary index of the Par-
kinson's Disease Questionnaire (PDQ-39) [14] was used to measure
global QoL and is well validated; scores ranged from 0 (best
possible QoL) to 100 (worst possible QoL).
Participants completed a schedule of neuropsychological tests.
Global cognitive function was assessed using the MMSE [15] and
Montreal Cognitive Assessment (MoCA) [16]. Attention was
measured using Power of Attention (PoA) and Digit Vigilance Ac-
curacy (percentage of correct targets detected) from the Cognitive
Drug Research (CDR) battery [17]. PoA is a composite score of the
mean time (msec) for Simple Reaction Time, Choice Reaction Time
and Digit Vigilance reaction time. Memory was assessed using the
number of correct answers from Pattern Recognition Memory and
Spatial Recognition Memory, and mean trials to success for Paired
Associate Learning from the Cambridge Neuropsychological Test
Automated Battery (CANTAB) [18]. Executive functionwas assessed
using the One Touch Stockings of Cambridge from CANTAB (num-
ber correct on first trial), phonemic fluency (number of word
generated in 60s beginning with the letter F) and semantic fluency
(number of animals generated in 90s). Visuospatial function was
evaluated using the pentagon copying item within the MMSE and
was graded using a modified 0e2 rating scale [19]. Language was
assessed using the naming (0e3) and sentence (0e2) items in the
MoCA.
Our schedule of neuropsychological tests preceded the intro-
duction of theMDS criteria for mild cognitive impairment (PD-MCI)
[20]; therefore, we used a modified MDS Level II criteria, described
previously by Yarnall et al. [7]. Briefly, participants were classified
as PD-MCI if they performed two standard deviations (SD) or more
below the mean of appropriate norms (controls) on at least two
neuropsychological tests across five cognitive domains: attention,
memory, executive function, language and visuospatial function.
For data that were not normally distributed, percentiles derived
from a normal distribution were used to estimate cut-offs [7]. A 2
SD cut off was used as recent studies suggest this is the optimal cut
off to distinguish PD-MCI from normal cognition (PD-CN) [21].
Subjective cognitive decline and functional independence were
determined through semi-structured interviews with participants
and/or their carers to enable PDD diagnosis using the MDS criteria
in appropriate cases [9].
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Statistical analyses were performed using SPSS software
(Version 21.0; SPSS, Inc., Chicago, IL). Data were examined for
normality of distribution with visual histograms and Kolmogorov-
Smirnov's test. Comparisons of means between two groups were
performed using independent t-tests or Mann-Whitney U tests,
depending on distribution. For more than two group comparisons,
one way ANOVA or Kruskal-Wallis tests were used as appropriate.
Repeated measures were examined using repeated measures
ANOVA or Friedman tests. Spearman's rank correlation was used to
test associations between variables. Multiple comparisons under-
went Bonferroni's correction. Principal component analysis (PCA)
using oblique oblimin rotationwas used to reduce the large number
of highly correlated neuropsychological assessments to a smaller
number of independent cognitive dimensions. This allowed an
evaluation of whether certain domains or groups of tests could be
used to predict QoL. Hierarchical regression was used to determine
significant predictors of QoL. Backwards stepwise regression was
used to determine a basic model of predictors involving: age, sex,
years of education, LED, GDS-15 score and MDS-UPDRS III; non-
significant predictors were excluded. Measures of cognition were
then entered to produce a final model.
R software (Version 3.0.1; R Foundation for Statistical
Computing, Vienna, Austria) and lme4 were used to perform linear
mixed effects analysis of the relationship between QoL and cogni-
tion from baseline to 36 months. A random intercept model was
used, where the intercept varied at the participant and time level.
Age, sex, years of education, LED, GDS-15 score and MDS-UPDRS III
score were entered into the model as fixed effects, as well as in-
teractions of time with depression score (GDS-15  Time), motor
severity (Time MDS-UPDRS III) and LED (Time  LED). A reduced
model was produced by excluding non-significant predictors to
which cognitive measures were added. Fit of the models was
assessed by likelihood ratio tests.
3. Results
At baseline, 219 participants completed assessments; over 36
months, seven participants were re-diagnosed as not having idio-
pathic PD (Fig. 1) and were excluded, leaving 212 PD participants. In
addition, 24 participants withdrew from the study, 21 were not
contactable (lost to follow up), and nine participants died. Thus 158
of 212 participants (75%) returned for evaluation at 36 months
(mean time interval 3.1 ± 0.2 years). Seven participants at 18
months and nine participants at 36 months did not complete the
PDQ-39 questionnaire and were excluded from the cross-sectional
analysis. There were no significant differences in baseline de-
mographics, global cognition or QoL between completers and those
lost to further evaluation (Supplementary Table 1).
At baseline, 21% of participants were classified as PD-MCI at 2
SDs below normative values. By 36 months, 14 participants (9%)
had developed PDD and 27% were classified as PD-MCI; seven
participants (4%) with baseline PD-MCI had reverted to normal
cognition. Participants with cognitive impairment were signifi-
cantly older, had completed fewer years of education and had lower
pre-morbid IQ (Table 1, p < 0.05 for all at each time point). At 18 and
36 month evaluation, post hoc analysis revealed that PD-MCI and
PDD participants had more severe motor disease than those with
normal cognition (PD-CN) (p < 0.01).
PDQ-39 scores were significantly higher in those with PD-MCI
compared to PD-CN at baseline (24.4 ± 16.5 vs. 16.8 ± 13.2,
respectively, p < 0.01), 18 months (26.8 ± 18.9 vs. 17.9 ± 14.3,
respectively, p < 0.01), and 36 months (25.0 ± 16.8 vs. 18.2 ± 14.9,
respectively, p < 0.01). QoLwas significantly poorer in patients withPDD compared to those with PD-MCI at 36 months (40.1 ± 17.9 vs.
25.0 ± 16.8, respectively, p < 0.01).
3.1. Principal component analysis
Principal component analysis using baseline data identified
three principal components: attention, memory/executive function
and global cognition (Supplementary Table 2). These principal
components accounted for 62% of the variance of baseline cognition
(12%, 40% and 10% respectively, for each component). Factor scores
were then calculated using the component score coefficient matrix
at baseline, 18 months and 36 months. Lower scores indicated
poorer cognitive function in each test.
Correlation analysis indicated a weak but significant association
between PDQ-39 and the attention factor score at baseline
(r ¼ 0.21, p < 0.01) after Bonferroni corrections were applied. At
18 months, weak but significant correlations were observed be-
tween QoL and memory/executive function (r ¼ 0.27, p < 0.01)
and global cognition (r ¼ 0.29, p < 0.01); attention was also
significantly correlated but not after Bonferroni corrections were
applied (r¼0.20, p < 0.05). At 36months, the correlation of PDQ-
39 scores with attention (r ¼ 0.42, p < 0.01), memory/executive
function (r ¼ 0.50, p < 0.01) and global cognition (r ¼ 0.39,
p < 0.01) were stronger, suggesting an increasing association over
36 months.
3.2. Baseline predictors of quality of life
Repeatedmeasures analysis showed PDQ-39 scores significantly
increased over time in participants with PD-MCI at baseline
(24.4 ± 16.5 vs. 27.9 ± 18.2 vs. 32.7 ± 20.8 at baseline, 18 and 36
months, respectively, c2 ¼ 11.2, p < 0.01), with a mean paired
change of 9.1 ± 15.0. This was compared to PD-CN participants at
baseline with a mean paired change of 3.0 ± 13.3 in PDQ-39 scores
over 36 months (c2 ¼ 7.6, p < 0.05).
Hierarchical regression was used to determine baseline pre-
dictors of QoL at 36 months. Backwards stepwise regression was
used to determine that fewer years in education, higher baseline
motor severity and higher baseline depression scores were signif-
icant predictors of poorer QoL 36months later (p< 0.05 for all). This
accounted for 30% of the variance (adjusted R2 ¼ 0.30, F ¼ 21.9,
p < 0.01).
Baseline MoCA score as a measure of global cognition, cognitive
classification (PD-CN or PD-MCI), and factor scores from the PCA
analysis were separately added to the basic model. Small but sig-
nificant changes were observed by adding baseline MoCA scores
and cognitive classification, accounting for 3% (DR2¼ 0.03, p < 0.05)
and 4% (DR2 ¼ 0.04, p < 0.01) respectively of the total variance
(Table 2). In contrast, baseline factor scores of cognition resulted in
the largest percentage change, accounting for 13% of the variance of
QoL at 36 months (DR2 ¼ 0.13, p < 0.01). However, only baseline
attentionwas significant (p < 0.01). The regression model including
baseline attention alone explained 11% of the variance (DR2 ¼ 0.11,
p < 0.01).
3.3. Longitudinal analysis of cognition and quality of life
Linear mixed effects modelling was used to determine the as-
sociation between changing cognition and QoL using all 212 par-
ticipants. Significant predictors of longitudinal PDQ-39 scores are
shown in Table 3; being younger, female, fewer years of education,
higher LED and persistent depression predicted poorer QoL over 36
months. Increasing PD motor severity over time (b ¼ 0.2, p < 0.01),
but not cross-sectional disease motor severity (b ¼ 0.1, p > 0.05),
predicted decreasing QoL. The model also suggested that time, in
Table 1
Demographic and clinical characteristics of participants by cognitive classification at baseline, 18 months and 36 months.
Baseline (n ¼ 212) 18 months (n ¼ 183) 36 months (n ¼ 149)
PD-CN
(n ¼ 167)
PD-MCI
(n ¼ 45)
p Value PD-CN
(n ¼ 124)
PD-MCI
(n ¼ 51)
PDD (n ¼ 8) p Value PD-CN
(n ¼ 95)
PD-MCI
(n ¼ 40)
PDD (n ¼ 14) p Value
Age (years) 65.1 (9.9) 68.7 (9.0) 0.024a 66.1 (9.4) 72.3 (8.3) 74.8 (6.3) <0.001b 66.5 (9.2) 71.9 (8.7) 75.3 (7.4) <0.001 b
Gender (male)y 104 (62) 30 (67) 0.728c 77 (62) 33 (65) 5 (63) 0.948c 59 (62) 28 (70) 10 (71) 0.566c
Education (years) 13.2 (3.5) 11.3 (3.5) <0.001d 13.4 (3.5) 11.2 (2.9) 12.1 (4.4) <0.001e 13.5 (3.5) 11.9 (2.9) 12.1 (3.9) 0.003e
NART 115.9 (9.4) 108.7 (11.4) <0.001d 116.8 (9.6) 110.3 (10.0) 107.3 (11.7) <0.001e 117.3 (8.0) 109.4 (12.6) 107.3 (11.0) <0.001e
UPDRS III Total 26.5 (11.0) 31.2 (14.2) 0.064d 30.1 (11.1) 40.7 (12.0) 48.1 (8.9) <0.001e 31.9 (12.9) 41.1 (15.0) 46.5 (15.8) <0.001e
Hoehn and Yahr
stage
1.9 (0.6) 2.1 (0.8) 0.039d 2.1 (0.5) 2.4 (0.6) 2.6 (0.7) 0.004e 2.0 (0.5) 2.2 (0.6) 2.7 (0.8) <0.001e
LED (mg/d) 175.7 (160.4) 190.1 (133.8) 0.188d 420.7 (233.0) 430.5 (256.1) 303.1 (123.6) 0.329e 512.4 (289.2) 588.4 (297.5) 493.1 (239.9) 0.585e
GDS-15 2.6 (2.4) 3.8 (3.2) 0.013d 2.5 (2.5) 3.5 (3.2) 3.0 (1.3) 0.074e 2.7 (2.4) 3.5 (2.6) 4.5 (2.8) 0.018e
PDQ-39 16.8 (13.2) 24.4 (16.5) 0.004d 17.9 (14.3) 26.6 (18.9) 28.3 (13.9) 0.006e 18.2 (14.9) 25.0 (16.8) 40.1 (17.9) <0.001e
MoCAz 26.2 (2.7) 22.3 (4.0) <0.001d 27.3 (2.7) 24.4 (3.1) 17.4 (3.7) <0.001e 27.3 (2.4) 23.8 (3.2) 19.6 (4.3) <0.001e
MMSE 28.9 (1.1) 28.0 (1.6) <0.001d 28.9 (1.3) 27.6 (1.7) 25.0 (2.2) <0.001e 28.9 (1.4) 27.4 (2.4) 24.4 (3.4) <0.001e
All figures are mean(standard deviation) except y where figures are n(%), z at baseline n ¼ 23 did not complete MoCA.
a ¼ independent t-test, b ¼ ANOVA, c ¼ Chi squared test, d ¼ Mann-Whitney U test, e ¼ Kruskal-Wallis.
PD-CN¼ Parkinson's disease with normal cognition, PD-MCI ¼ Mild cognitive impairment in Parkinson's disease using the 2 standard deviation cut-off, PDD ¼ Parkinson's
disease dementia, NART¼ National Adult Reading Test, UPDRS III ¼Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III, LED ¼ Levodopa equivalent
dose, GDS-15 ¼ Geriatric Depression Scale, PDQ-39 ¼ Parkinson's Disease Questionnaire, MoCA ¼Montreal Cognitive Assessment, MMSE ¼Mini-Mental State Examination.
Table 2
Regression coefficients and model fit of baseline cognitive predictors of quality of life at 36 months.
Predictors in modela b t p 95% CI for b R R2 Adj R2 Std. Error D R2
Lower bound Upper bound
Baseline MoCA 0.17 2.27 0.025 1.6 0.11 0.58 0.33 0.31 14.11 0.03
Baseline PD-MCI 0.2 2.91 0.004 2.86 14.95 0.6 0.35 0.34 13.7 0.04
Baseline factor scores e e e e e 0.64 0.41 0.38 13.36 0.13
Baseline Memory/Executive function factor score 0.11 1.28 0.203 5.4 1.16 e e e e e
Baseline Attention factor score 0.3 3.64 <0.001 2.27 7.68 e e e e e
Baseline Global cognition factor score 0.09 1.03 0.305 4.8 1.52 e e e e e
Baseline Attention factor score 0.35 4.48 <0.001 3.26 8.42 0.63 0.39 0.37 13.5 0.11
MoCA ¼ Montreal Cognitive Assessment, PD-MCI 2 SD ¼ PD-MCI classified using the Movement Disorder Society with 2 standard deviation (SD) cut off.
a Model also includes: years of education, Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III score and Geriatric Depression Scale score.
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p < 0.01).
MoCA, cognitive classification and PCA factor scores plus in-
teractions with time were separately added to the basic model
(Table 3). Decreasing MoCA scores over time predicted decline in
QoL. Neither PD-MCI classification nor PDD at a particular time
point were significant predictors of QoL. However, the interaction
of PDD with time was a significant predictor of decreasing QoL
scores (b ¼ 10.3, p < 0.05), suggesting that developing PDD over
time significantly reduces an individual's QoL. The PCA factor scores
did not significantly predict cross-sectional QoL. However,
declining attention over time was a significant predictor of
decreasing QoL (b ¼ 2.3, p < 0.001).
Log-likelihood ratio comparing the fit of the models showed the
basic model plus PCA factor scores was a significantly stronger
model compared to the basic model, MoCA or cognitive classifica-
tion (c2 ¼ 578.8, p < 0.001). Therefore, changes in attention may be
more accurate in predicting poorer long term QoL.
4. Discussion
This is the first study to investigate the longitudinal effects of
cognitive impairment on QoL using a range of validated assess-
ments in a large group of patients with newly diagnosed PD. We
have demonstrated that cognitive impairment contributes to lon-
gitudinal QoL change in people with PD, and that decline in
attention has the greatest predictive power.
Participants with PD-MCI at baseline reported a mean increase
of nine points in PDQ-39 scores over 36months, indicating that QoLdeteriorated over time. This magnitude of change has been sug-
gested to be clinically significant [22] and was three times greater
compared to participants classified as PD-CN at baseline, which
would not be regarded as clinically meaningful change.
Baseline PD-MCI was a predictor of poorer QoL at 36 months,
although the proportion of variance explained was small. Another
longitudinal study reported similar findings, albeit with a shorter
duration of follow-up and less comprehensive neuropsychological
assessments [3]. In our study, it was the development of dementia,
rather than PD-MCI, that was associated with decline in QoL. This is
consistent with a cross-sectional study by Leroi et al. [2] who re-
ported that subjects with PDD had significantly worse QoL than
participants with normal cognition or PD-MCI.
A small but significant change in QoL at 36 months was pre-
dicted by lower MoCA scores at diagnosis. Multilevel modelling
showed declining MoCA scores over 36 months predicted
decreasing QoL. Therefore, the MoCA could be potentially useful to
clinicians; it is a measure of global cognition that is quick and
simple to administer, but could have utility in anticipating future
difficulties for individuals with PD.
However, greater predictive accuracy may come from the use of
more specific cognitive assessments. PCA permitted the evaluation
of clusters of cognitive tests in relation to QoL. Attention was the
only significant predictor of QoL, either as a baseline predictor or
using multilevel modelling. Baseline attention factor scores also
accounted for the largest change in variance between models of
PDQ-39 scores at 36 months, and a stronger predictive power
compared withMoCA or cognitive classification longitudinally. This
is notable, since few studies have evaluated specific cognitive
Table 3
Predictors of quality of life using mixed effects modelling.
b Std.
Error
t p
Basic model
Gender (Female) 3.7 1.3 2.7 0.007 **
Education (Years) 0.7 0.2 3.6 <0.001 ***
Age 0.3 0.1 4.4 <0.001 ***
LED 0.02 0.0 3.8 <0.001 ***
GDS-15 3.3 0.4 8.2 <0.001 ***
Time (Assessment) 3.5 1.3 2.6 0.009 **
UPDRS III 0.1 0.1 0.3 0.785
UPDRS III over Time 0.2 0.0 5.1 <0.001 ***
GDS-15 over Time 1.1 0.1 8.2 <0.001 ***
Basic model þ MoCA
MoCA 0.2 0.3 0.8 0.448
MoCA over Time 0.4 0.1 3.1 0.002 **
Basic model þ Cognitive classification
PD-MCI 2.1 2.6 0.8 0.433
PDD 16.6 10.9 1.5 0.129
PD-MCI over Time 0 1.2 0 0.973
PDD over Time 10.3 4.0 2.6 0.011 *
Basic model þ Factor scores
Memory/executive function 1.0 1.3 0.7 0.457
Attention 1.9 1.3 1.5 0.13
Global Cognition 0.1 1.3 0.0 0.971
Memory/executive function over Time 1.1 0.6 1.6 0.107
Attention over Time 2.3 0.7 3.5 <0.001 ***
Global Cognition over Time 0.4 0.6 0.7 0.492
* p < 0.05, ** p < 0.01, *** p < 0.001.
GDS-15 ¼ Geriatric Depression Scale, UPDRS III ¼ Movement Disorders Society-
Unified Parkinson's Disease Rating Scale Part III, LED ¼ Levodopa equivalent dose,
MoCA ¼ Montreal Cognitive Assessment, PD-MCI ¼ PD-MCI classified using the
Movement Disorder Society with 2 standard deviation (SD) cut off,
PDD ¼ Parkinson's disease dementia.
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poorer visual attention/memory was associated with poorer QoL,
whilst another study also found that participants with attentional/
memory deficits reported increased PDQ-39 scores [24]. However,
neither of these studies examined attention as an isolated cognitive
domain. One study found that attentional deficits in PDD were
significantly detrimental to both basic and instrumental ADL [5].
These include activities such as: washing, dressing, eating and
managing medications, as well as social interactions, keeping ap-
pointments and engagement in leisure activities, which are
important in maintaining good quality of life. Impaired attention is
a feature of PDD [25]; therefore, attention may be an alternative
marker for the development of PDD and it could be postulated that
it is actually incipient PDD that is more important for QoL. None-
theless, our findings have implications for clinicians as in-
terventions targeting attention could significantly improve QoL.
Younger age, higher depression scores and increased disease
severity were associated with poorer QoL, both in cross-sectional
and longitudinal analysis. This is consistent with previous studies
[4,23,26]. Being female predicted having poorer QoL, as did
increased LED score. Gender as a predictor of QoL is an inconsistent
finding in the literature with better QoL being reported in males,
females or no significant differences at all [23,26]. Years in educa-
tion seemed to be a protective factor, which could be indicative of
the role of education and IQ in cognitive reserve [27]. Interestingly,
increasing time as a variable predicted improved QoL scores. This
could indicate a degree of successful adjustment and coping in the
absence of declining motor symptoms and cognition, which is
consistent with findings in other studies [6].
This study pre-dated the MDS PD-MCI criteria and is therefore
limited in its assessment of language and visuospatial function,
therefore amodified versionwas used. However, the concept of PD-
MCI has been debated and as yet PD-MCI criteria have not beenvalidated, with cut offs of 1, 1.5 and 2 SD below normative values all
being used. 312 patients declined participation, which may intro-
duce selection bias. As with many longitudinal studies, missing
data were problematic (Supplementary Table 3). This reduced the
statistical power that requires complete datasets, such as linear
regression and PCA. The missing CDR data could have affected PD-
MCI classification at 36 months with the false-negative (Type I er-
ror) classification of PD-CN in some participants. However, differ-
ences between participants were examined graphically and
analytically; participants were representative of the whole sample,
with no significant differences in global cognition or QoL scores.
Additionally, linear mixed effect modelling is able to handle
missing data and does not remove participant data listwise. The
small number of participants who did not return for further eval-
uation may have been those with a more rapid decline in PD,
cognition and QoL and would therefore have been of particular
interest to this study. However, baseline scores tested analytically
and graphically did not reveal any significant differences. Some
participants improved in their neuropsychological assessment
scores which could be due to a learning effect, medication effects or
normal fluctuations in cognition. We used a time interval of 18
months between testing, which has been suggested as an appro-
priate length of time to negate practice effects. Finally, we used the
PDQ-39 as a PD specific QoL measure; it has been suggested that a
generic should also be used when using disease-specific QoL
measures. However, the PDQ-39 is well validated and recom-
mended by some for measuring QoL in PD [28].
In summary, cognitive impairment had a significant, albeit
small, role in determining QoL. Over three years following diag-
nosis, most patients were cognitively stable and for them QoL was
not greatly influenced by cognition. Patients who were categorised
as having PD-MCI had worse QoL scores. A minority of people
developed PDD over three years, where cognition had a much
greater impact on QoL. Brief clinical tests could predict to some
degree those people at risk of declining QoL, but more sophisticated
attentional tasks may have greater predictive power. Pharmaco-
logical interventions, in the form of rivastigmine [29], and non-
pharmacological interventions, such as cognitive rehabilitation
focused on attention [30], may be useful in improving attention and
concentration in PD patients and, therefore, QoL. Further longitu-
dinal studies are required to substantiate the findings of this study
and to better evaluate the impact of treatments for attentional
decline.
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